Orchestra BioMed Holdings, Inc. (OBIO) Financial Analysis & Valuation | Quarter Chart
Orchestra BioMed Holdings, Inc. (OBIO)
OBIOPrice: $4.35
Fair Value: 🔒
🔒score
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic ... more
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flag... more
Description
Shares
| Market Cap | $254.57M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Hochman |
| IPO Date | 2020-08-04 | CAGR | -0.18% |
| Employees | 70 | Website | orchestrabiomed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.76% | Total Yield | 0.76% |
OBIO chart loading...
Fundamentals
Technicals
| Enterprise Value | $90.54M | P/E Ratio | -3.92 |
| Forward P/E | -2.23 | PEG Ratio | — |
| P/S Ratio | 8.33 | P/B Ratio | 56.47 |
| P/CF Ratio | -0.28 | P/FCF Ratio | -0.4 |
| EPS | $-1.11 | EPS Growth 1Y | 13.12% |
| EPS Growth 3Y | 290.34% | EPS Growth 5Y | — |
| Revenue Growth 1Y | 6.46% | Gross Margin | 0.93% |
| Operating Margin | -24.21% | Profit Margin | -23.67% |
| ROE | -2.89% | ROA | -1.63% |
| ROCE | -2.77% | Current Ratio | 2.1 |
| Quick Ratio | 2.09 | Cash Ratio | 1.1 |
| Debt/Equity | 6.68 | Interest Coverage | -1979.64 |
| Altman Z Score | -13.25 | Piotroski Score | 3 |